Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system Aminex Therapeutics, Inc., a...
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...
Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengt...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecos...
Parse Biosciences and Graph Therapeutics (Graph) announced a strategic partnership to create one of the largest and most comprehensive immune cell pertur...
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...
Affidea Group, Europe’s leading provider of advanced diagnostics, community-based polyclinics and specialised healthcare services including oncolog...
RISA Labs, a company pioneering an AI operating system for oncology, announced the closing of an $11.1 million Series A funding round. The financing was ...
PathAI, a global leader in AI-powered pathology, announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight® Dx1, Pa...
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myelo...
- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, ...
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and de...
© 2026 Biopharma Boardroom. All Rights Reserved.
